Ananda Developments PLC - London-based pharmaceutical company developing cannabinoid-based medicines for chronic pain conditions - Says the Scottish government's Chief Scientist Office, responsible for funding research in NHS Scotland, will provide non-dilutive funding for Ananda's randomised controlled trial. The RCT will test Ananda's MRX1 sublingual cannabidiol (CBD) oil formulation versus a matching placebo, in 100 endometriosis patients. Endometriosis is a chronic condition affecting roughly 190 million people assigned female at birth worldwide. Ananda intends to "investigate if a future large scale, UK-wide trial to determine whether a cannabinoid can reduce endometriosis-associated pain is possible."
Chief Executive Officer Melissa Sturgess says: "Our objective is to have MRX1 included by the NHS as an efficacious and cost-effective treatment for pain associated with endometriosis. Getting NHS funding for this trial using MRX1 is a clear statement of the importance of endometriosis as a public health issue and we believe clearly demonstrates the interest in the use of cannabidiol as a potential treatment for endometriosis and other complex chronic inflammatory pain conditions by the UK's public health bodies."
Current stock price: 0.45 pence, up 3.3% on Tuesday in London
12-month change: down 13%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved
